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receiving high doses from BT all have received a homogenous dose of 
EBRT. From patterns of care studies we know that parametrial 
boosting by EBRT is still popular especially in advanced stages. 
However, the IGABT data reported so far does not include a 
parametrial boost but has relied only on whole pelvic EBRT to a dose 
level of about 45-50 Gy. From this level IGABT has then been used to 
reach a D90 of 85-90 for HR CTV. This also implies an almost 50/50 
balance of dose between EBRT and BT. When IMRT is being used 
special attention is needed to assure dose homogeneity around the BT 
target to avoid unintentional OAR overdosing.  
For the advanced level user already having picked the low hanging 
fruits of IGABT a considerable challenge is to further improve the 
differential dose delivery afforded by this technique. Emerging data 
from multicenter studies show a significant correlation between D90 
of HR CTV and local control with more than 90% continuous local 
control obtained for D90 of HR CTV > 90 Gy. To achieve such a high 
dose level a combined intracavitary-interstitial technique including 
additional needles will no doubt have to be implemented. With the 
improved local control a new frontier in terms of regional and 
metastatic disease are emerging requiring new studies for combining 
IGABT with advanced EBRT techniques. Also other normal tissues are 
showing up as being clinically important and among them the vagina is 
essential to further improve the therapeutic ratio. However, along 
these new initiatives a major challenge will be to keep IGABT 
practical by offering a possibility of different levels of reporting for 
routine clinical treatment and research. 
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Introduction: Brachytherapy (BT) is an essential part of vaginal cancer 
treatment. In 4D image guided adaptive BT (IGABT), the dose 
distribution is adapted to a target which changes in shape and volume 
during the course of therapy, while respecting the organs at risk (OAR) 
dose constraints. IGABT has improved the outcome in gynaecological 
cancer. Several challenges and pitfalls of this approach were 
recognized, in particular (but not limited to) uncertainties of various 
steps of IGABT procedure, limited sectional imaging availability and 
complexity of application techniques. Some of the main challenges, 
pertaining specifically to vaginal cancer, are discussed below. 
Application techniques: Various application techniques have been 
used for vaginal cancer BT in the past. Implementation of sectional 
imaging enables detailed assessment of the patterns of tumor spread, 
regression and topography at IGABT. Based on such evaluation, 
development of innovative vaginal BT applicators and refinement of 
application techniques represents a challenging avenue of future 
research. Off-line or real-time intraoperative MRI or ultrasound 
guidance is a promising approach that has proven helpful in achieving 
optimal interstitial implant geometry in vaginal cancer [Stock RG, et 
al. IJROBP 1997, Weitmann HD, et al. Strahlenther Onkol 2006, 
Viswanathan AN, et al. IJROBP 2006]. 
Imaging, target volume concepts, contouring and dose volume 
parameters: Technical precision  of treatment delivery has likely 
surpassed our ability to estimate the location of tumor spread, 
meaning that contouring uncertainties may compromise the overall 
gain of IGABT [Petric P, et al. RadiotherOncol 2013, submitted]. 
Optimal imaging, adequate training and respecting the contouring 
guidelines are the main strategies to minimize these uncertainties. 
MRI has been recommended as the gold standard for cervix cancer 
IGABT. In the absence of specific guidelines, the GEC ESTRO 
recommendations for cervix cancer IGABT may be applied in vaginal 
cancer with some adaptations [Dimopoulos JC, et al. IJROBP 2012, 
Petric P, et al. in: Viswanathan et al., eds. Gynecologic radiation 
therapy, Springer 2011, Pötter R, et al. Radiother Oncol 2006, Haie 
Meder C, et al. Radiother Oncol 2005]. Dimopoulos et al. applied 
these concepts in 13 vaginal cancer patients and found the dose-
volume parameters and clinical outcome to be in a range, comparable 
to experience in cervix cancer [IJROBP 2012]. The validity of this 
approach would benefit from confirmation in further studies. Limited 
availability of MRI remains a limitation for wider implementation of 
IGABT [Guedea F, Radiother Oncol 2007] and fuels the ongoing efforts 
to systematically validate the role of ultrasound and computed 
tomography in this field. 
Clinical outcome: Reports on clinical benefits of vaginal cancer IGABT 
were published [Dimopoulos JC, et al. IJROBP 2012, Dimopoulos JC, et 
al. Onkologe 2009, Viswanathan AN, et al. IJROBP 2006, Weitmann 
HD, et al. Strahlenther Onkol 2006]. However, they are limited to 
small retrospective series and the evidence for vaginal IGABT is mainly 
based on extrapolations from larger studies in cervix cancer. 
Importantly, the specific relationships of vaginal tumors to the nearby 
organs at risk represent a somewhat different challenge than in cervix 
cancer. The ability to preserve vaginal anatomy and function, 
interlaced with the complex hormonal and psychosexual consequences 
of treatment, has important quality of life implications. The role of 
concurrent chemoradiotherapy and adjuvant systemic therapy in 
vaginal cancer has not been tested in clinical trials. These topics are 
gaining increased attention in cervix cancer IGABT and should be 
adressed also in vaginal cancer. 
Conclusions: The IGABT concepts, developed for cervix cancer, 
appear to be applicable to vaginal cancer with some adaptations. 
Prospective multicenter studies are needed to further establish the 
impact of IGABT on treatment outcome with an emphasis on quality of 
life issues, but will be challenging to conduct due to the low incidence 
of this disease. 
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Introduction: Vulvar tumours account for 3% to 5% of the female 
reproductive tract cancers. The diagnosis of primary vulvar malignant 
tumours is usually made in postmenopausal women. Delay in the 
diagnosis is among the characteristics of the disease. Vulvar tumours 
are easily accessible to clinical examination. The pattern of 
dissemination is mostly lymphogenic with inguinofemoral lymph node 
metastases. Tumor characteristics and lymph node status are 
integrated into the 2009 FIGO classification. 
Treatment: The standard treatment for vulvar squamous cell 
carcinoma is surgery. External irradiation, brachytherapy (BT) and 
chemotherapy are either adjuvant treatment options or exclusive 
treatment options in advanced disease or in case of surgical contra-
indications.Radical vulvectomy with “en bloc” bilateral 
inguinofemoral and pelvic lymphadenectomy used to be the standard 
treatment. Wide local incision is nowadays recognized as an 
alternative to radical vulvectomy if free microscopic margins of at 
least 8mm and preferably 20mm can be achieved. After wide local 
excision, radiotherapy is indicated in case of positive margins or with 
margins< 3mm if re-excision is not possible. In this situation, a total 
dose of45Gy-50Gy in 25-28 fractions is recommended to control 
potential micro-metastases. Interstitial BT can be combined to 
external irradiation depending upon tumour location. In case of 
contra-indication to surgery or in advanced tumours, or in recurrent 
tumors, radiotherapy has proven its efficacy. A total dose of 45 Gy is 
delivered to the pelvis, usually combined with interstitial BT to a total 
dose of 60 Gy-85 Gy.  
Implantation techniques: Two major techniques are used,depending 
upon tumor extension. When the tumor is mainly located in the 
vulva,and more particularly in the labia, interstitial BT is performed 
using platictube technique, usually implanted parallel to the labia. In 
case of larger tumors with para-urethral and/or para-vaginal area 
involvement, interstitial BT can be combined with endocavitary BT. 
Blind steel needles or plastic tubes are free-handly inserted parallel to 
the vaginal axis or placed via a template. 
Clinical target volume (CTV) definition: Vulvar malignancies are best 
imaged with magnetic resonance imaging (MRI) to identify local-
regional extent of disease. By contrast with cervical or vaginal cancers 
however, CTV definition in vulvar postoperative BT is mainly based on 
histopathological findings while both clinical assessment and MRI are 
used in case of exclusive irradiation. So far, no recommendation for 
vulvar cancer image guided adaptive(IGA) BT has been published. 
Extension from GEC-ESTRO cervix recommendations are difficult in 
this situation, as organs at risk are different: urethra, anal canal, and 
vagina (if not involved). Catheter reconstruction is an issue in 
interstitial BT as the tube diameter does not allow any visible filling 
when MRI is used.  
Clinical outcome: Vulvar IGABT results are very limited. The series 
are limited in terms of patient number and  usually present 
retrospective data. Seeger A, Strahlenther Onkol 2006, reported 
IGABT in 9 patients while larger series (Perez C, IJROBP 1998, Pohar S, 
IJROBP 1995) were dealing with X-ray-based BT. 
Conclusion: IGABT has not been extensively reported in the 
literature. Due to the rarity of the tumor, multicentre studies appear 
to be necessary to better establish the role of IGABT in the 
management of postoperative or exclusive treatment of vulvar cancer.  
 
 
 
